An overview of engineering advancements for complex Oral Solid Dose (OSD) coatings
Coating technologies have been a mainstay in OSD drug development for many decades and deployed successfully in hundreds of drug products for multiple therapeutic areas. With increasingly complex compounds emerging from the discovery pipeline and a broader range of dosage demands in today’s OSD market, coatings must be deployed more innovatively and expertly than ever before to overcome challenges. Certain OSD products such as those that require a low dose, flexible dose, low potency or a novel shape are viewed as highly problematic for coating strategies due to control issues or difficulties at commercial scale-up.
Pfizer CentreOne’s oral solid dose experts discuss how advances in the mathematics and engineering involved in understanding the process can tackle these challenges and ensure functional coating and drug layering continue to be a viable solution for the next generation of OSD drug products. Discover how coatings expertise could transform your OSD drug by clicking on the link.
Key Learning Objectives
- Understand the oral solid dose challenges that can be tackled with coatings through expert mathematics and engineering
- Explore the range of coating techniques and technologies
- Learn how these coatings can be scaled and transferred effectively for commercial manufacturing
Kieran Coffey, Technical Services Lead, Pfizer Ireland Pharmaceuticals, Newbridge
Kieran Coffey leads the Technology Innovation Centre at Pfizer Newbridge which is a small-scale manufacturing and development facility. The Pfizer Newbridge site specializes in complex oral solid dose formulations and has a history of more than twenty-five years successfully delivering products to patients across the globe. Kieran has extensive experience in process scale-up, tech transfer, process development and optimization. He has lead the co-development and supply of material for clinical supply and the commercialization of pipeline products. Kieran graduated with a BSc. (Hons) in Analytical Science from Dublin City University and a GradDip (Hons) in Chemical Engineering from the University of Limerick.
Amy Trotch, Senior Manager, North America Contract Manufacturing Drug Product Sales, Pfizer CentreOne
Amy Trotch is Sr. Business Development Manager at Pfizer CentreOne, and is responsible for working with third-party biopharma's in the U.S. Amy is an experienced biopharma/biotechnology professional with over 12 years in research, business development, sales and account management, strategic marketing, and public relations in all major marketplaces, including academic, government, and commercial. With a passion for the sciences, both the life sciences and social sciences, she attended Cleveland State University, receiving a B.S. degree in Biology and a B.A. degree in Anthropology. She has served on the Pfizer CentreOne’s business development team since May 2017, with a heavy focus on its Oral Solid Dose business.